降钾药物治疗非急诊高钾血症:药理学、剂量与疗效比较
本文综述非急诊高钾血症的降钾药物,包括阳离子交换树脂、聚合物及新型钾结合剂如聚苯乙烯磺酸钠、patiromer和环硅酸锆钠。这些药物在药理学、作用机制、临床疗效(起效与降钾幅度)、剂量给药及安全性和不良反应方面存在差异,本文评估这些特征及临床证据与安全性顾虑。
要点
- 非急诊高钾血症常用降钾药物包括聚苯乙烯磺酸钠、patiromer和环硅酸锆钠。
- 不同降钾药物在药理学、起效速度、降钾幅度及安全性方面存在差异。
- 选择降钾药物需综合考虑临床证据与安全性顾虑。
核心结论
- 降钾药物在药理学、作用机制、临床疗效、剂量给药及安全性方面存在差异,需综合评估。
研究设计与样本
- 综述,评估降钾药物治疗非急诊高钾血症的药理学、剂量与比较疗效。
主要发现
- 高钾血症常见于心力衰竭、肾脏病、糖尿病或使用影响肾素-血管紧张素-醛固酮系统药物的患者。
- 血清钾升高常由尿钾排泄受损、细胞钾摄取不足、严重心力衰竭、使用影响血钾药物或多种因素组合所致。
- 降钾药物包括阳离子交换树脂、聚合物及其他新型钾捕获机制,如聚苯乙烯磺酸钠、patiromer和环硅酸锆钠。
临床怎么用
- 临床选择降钾药物时需考虑其药理学、起效与降钾幅度、剂量给药及安全性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperkalemia represents a common and potentially life-threating electrolyte abnormality, a complication frequently observed in patients with heart failure, kidney disease, diabetes or in those receiving drug therapies influencing the renin-angiotensin-aldosterone system. Elevated serum potassium levels are often the result of impaired urinary potassium elimination, inadequate or reduced cellular potassium uptake, severe heart failure, use of medications influencing potassium levels in the circulation, or, more commonly, a combination of these factors. Strategies for the treatment of nonemergent hyperkalemia include the use of cation-exchange resins, polymers or other novel mechanisms of potassium trapping, including sodium polystyrene sulfonate, patiromer and sodium zirconium cyclosilicate. These agents differ in their pharmacology and mechanism of action, clinical efficacy, including onset and extent of potassium-lowering effect, dosage and administration, and potential safety and adverse effect profiles. In this review, an evaluation of these characteristics, including clinical evidence and safety concerns, in the management of nonemergent hyperkalemia will be explored.
引用
- Bridgeman MB, Shah M, Foote E, et al. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy. Nephrol Dial Transplant. 2019. PMID: 31800078. doi:10.1093/ndt/gfz223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。